Cellectar Biosciences Inc (NASDAQ: CLRB) announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients that have received at
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi
Vincerx Pharma Inc (NASDAQ: VINC) shares are trading higher after the company released clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for
Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.